INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd Announces that Zenas BioPharma, Inc. (ZBIO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc. and is pending in the District of Massachusetts [1]. - Investors who purchased Zenas BioPharma securities during its IPO on September 13, 2024, have until June 16, 2025, to seek lead plaintiff status [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. Group 2: Financial Impact - Zenas BioPharma sold over 13 million shares at $17.00 per share during its IPO [2]. - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, representing a decline of 48.7% from the IPO price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows investors to seek lead plaintiff status if they have suffered losses related to the IPO [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].